Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 20, 1996

View Archived Issues

Ortho describes new analgesics

Potential new analgesic agent from SmithKline Beecham

Post-surgical pain management with dynorphin A

Combination analgesic progresses through clinical trials

Novel antiproliferative agents from RDF

Amgen claims wound-healing growth factor

Hair loss product to enter pivotal trials in Europe

New quinolone from Bayer undergoing extensive evaluation

Safe, broad-spectrum quinolones from Wakunaga

Antibacterial compositions for MRSA

Antifungal cyclohexapeptides from Merck & Co.

New topical triazole antifungal agent from Kaken

Optically active triazole antifungal agent from Takeda

Sixteenth approval for Amphotec

New tablet formulation of valaciclovir

Anti-HIV compounds from Janssen

Promising preliminary results with DMP-266

AIDS treatment to enter clinical trials in Japan

Expanded access program for HIV protease inhibitor

Canadian clearance for HIV protease inhibitor

ACTG to evaluate 141W94/VX-478

U.S. patent for herbal medication with potential in AIDS

University of Kentucky's PC-16 for arthritis

Monoclonal antibody effective in rheumatoid arthritis

New formulation of ciclosporin

Improved influenza vaccine enters clinical trials

New introduction for Prograf

Sandoz licenses transplant patents from Seragen

Nitrogen mustard prodrugs from CRC Technology

SAMDC inhibitors from Ciba-Geigy

Further approval recommended for Novantrone

XR-5000 advances through clinical trials

CI-958 for treatment of prostate cancer

Taxotere-doxorubicin com0bination as first-line treatment of advanced breast cancer

New launch for Arimidex

RPR reports novel protein farnesyltransferase inhibitors

HEK4-binding protein from Amgen

Novel anticancer tyrosine kinase inhibitors from Pharmacia & Upjohn

New cancer therapy from The Liposome Company advances to full development

Pfizer describes anticancer application for known antidepressant

Potential DNA vaccine for B-cell lymphoma

Pharmacyclics signs manufacturing and supply agreement for texaphyrin products

First patent for IL-15

Xalatan Solution now available for glaucoma

AGN-193080, a peripherally acting alpha2-agonist from Allergan

Wakamoto claims diclofenac eyedrop formulation

Prevention of bone loss with alendronate

Pierre Fabre investigates ACAT inhibitors

Bristol-Myers sets up program for heart attack prevention

NPY antagonists from Glaxo Wellcome

New indication claimed for EPO

Immunex issued first patent on blood stem cell factor

Dental anesthetic patch introduced in the U.S.

Ultrasound contrast agent for infertility in women

Joint venture to develop DNA-based diagnostic tests

First launch for colorectal carcinoma diagnostic

The effects of clonidine on sleep

American Home Products investigates 5-HT1A antagonists for anxiety

New CNS agents from American Cyanamid

Glaxo Wellcome identifies potential anxiolytic agents

Mitochondrial benzodiazepine receptor (MBR) ligands as potential anxiolytics

Anxiolytic/antidepressant approved in Japan

New dopamine D4 receptor antagonists from Taisho and Nihon Nohyaku

Fluphenazine ANDA approval

Hoechst Marion Roussel reports new antidepressants

Forest prepares NDA submission for antidepressant

Bristol-Myers Squibb/Panlabs/Tripos collaboration

New transdermal delivery system for natural hormones tested preclinically

Vasogen granted U.S. patent for delivery technology

Broad patent coverage for transgenic technology

Innovir and IRBM collaborate on new uses for enabling technology

Duramed acquires Hallmark

Roche-Bayer U.S. joint venture

Chiron renames vaccine unit

Merck & Co.-Chugai joint venture

Generic clonazepam approved

Idebenone evaluated in Huntington's disease

Roquinimex in MS

Antiemetic 5-HT3 antagonist launched in Japan

Bayer patents new compounds for CNS disorders

Forest prepares submission for Alzheimer's disease product

Metabotropic glutamate antagonists from Novo Nordisk

Metabotropic glutamate receptor antagonists from Lilly

Another series of mGluR antagonists from Lilly

Glutamate inhibitor progresses through the pipeline

Anti-IL-8 antibodies claimed by Genentech

5-LO inhibitor from Bristol-Myers Squibb

Schering AG investigates LTB4 inhibitors

LTD4 antagonist selected for further evaluation by Menarini

Customized asthma treatment introduced in the U.S.

Sepracor updates progress on (R)-albuterol

Zambon's ACE/NEP inhibitors for cardiovascular indications

Renin inhibitors in cardiovascular disease

Valaciclovir for restenosis

Use of bisaramil in oxidative stress-related conditions

AMI and magnesium supplementation

PLC Systems can halt randomization to medical therapy in TMR trial

Calcium-antagonist effects of estrogen

Anticoagulant for treating blood clots approved in Canada

New prostacyclins from Asahi Glass

Bristol-Myers Squibb to acquire prostacyclin analogue for claudication

Antiplatelet ketoprofen analogue from Fuji Chem.

Merck & Co. continues to investigate 5alpha-reductase inhibitors

New agents for BPH from Abbott

NC-1800 advances through clinical trials

Novel proton pump inhibitors from Dainippon

Second pivotal trial for Carrington's ulcerative colitis product

Prokinetic macrolides reported by Abbott

Clinical trials with Gilead Sciences' GS-840

New indications discovered for Ligand's retinoid compound, Targretin

Troglitazone nearing launch

New use for 5-HT2 antagonist

Tulane U. investigates GHRH agonists

Vivus seeks approval for impotence treatment

Another new use claimed for raloxifene

New combination for contraception in males

New tocolytics from Merck & Co.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...